Company intelligence / Profile preview

Elucidate Bio

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Elucidate Bio is a biotechnology company focused on developing precision medicines for neurodegenerative diseases. The company leverages a proprietary platform to identify and develop small molecule therapeutics that modulate protein homeostasis and autophagy pathways. By targeting the underlying mechanisms of protein misfolding and aggregation, Elucidate Bio aims to provide transformative treatments for conditions such as Alzheimer's disease and Parkinson's disease. The company is led by experienced industry veterans and is currently in the pre-clinical stage of development.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Elucidate Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elucidate Bio.

Explore the full profile